Universe Pharmaceuticals INC (UPC) stock
UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30
$1.51−0.02 (-1.31%)
Close on Nov 13, 2026Market cap $850.64KP/E –Yield –
Universe Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $671.76M, down 77.8% from the year before. The highest annual figure on record is $4.86B in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $671.76M | -77.8% |
| FY2024 | Sep 30, 2024 | $3.03B | -37.6% |
| FY2023 | Sep 30, 2023 | $4.86B | +63457.2% |
| FY2022 | Sep 30, 2022 | $7.64M | +39.9% |
| FY2021 | Sep 30, 2021 | $5.47M | +837.3% |
| FY2020 | Sep 30, 2020 | $583.13K | -5.7% |
| FY2019 | Sep 30, 2019 | $618.44K | – |
See a number that looks wrong?